Trinity Biotech stock declines after crossing below SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2025
0mins
Should l Buy TRIB?
Trinity Biotech PLC's stock fell by 20.31% after crossing below the 20-day SMA, reflecting a challenging trading environment.
This decline occurs amid broad market strength, with the Nasdaq-100 and S&P 500 both showing gains. However, the stock's performance is influenced by recent news regarding a significant order for 9 million units of its TrinScreen rapid HIV test, which is expected to enhance revenue visibility and support the company's turnaround strategy. Despite this positive development, the stock's movement suggests sector rotation as investors reassess their positions.
The implications of this stock movement indicate a complex market reaction, where positive company news is overshadowed by broader market dynamics. Investors may need to monitor the company's upcoming financial performance and market conditions closely.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIB
About TRIB
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trinity Biotech Reports FY 2025 Financial Results
- Revenue Decline: Trinity Biotech reported FY 2025 revenue of $43.8 million, a 28.9% year-over-year decrease, indicating significant sales challenges amid intensified market competition and weak product demand, which may impact future liquidity.
- Increased Net Loss: The company recorded a net loss of $37.4 million, up from $31.8 million in 2024, which included a one-off IFRS charge of $10 million related to modifications in Perceptive financing arrangements, highlighting financial management pressures.
- Adjusted EBITDA Improvement: The adjusted EBITDA for 2025 was negative $5.9 million, an improvement from negative $11.3 million in 2024, suggesting some progress in cost control despite the overall financial situation remaining challenging.
- Financing Agreement Signed: Trinity Biotech entered into a $25 million standby equity purchase agreement with investors to strengthen its capital structure and provide operational funding, reflecting proactive measures in seeking financial stability.
See More
Trinity Biotech Appoints New Head of North America Operations
- Executive Appointment: Trinity Biotech has appointed Jerry Lydon as Head of North America Commercial Operations, aiming to enhance revenue growth and profitability in its core diagnostics business, reflecting ongoing progress in the company's Comprehensive Transformation Plan.
- Product Upgrade: The Premier HbA1c 9210™ platform has received the prestigious
See More
Trinity Biotech Announces Positive Results for Enhanced Prostate Cancer Test
- Clinical Study Results: Trinity Biotech's EpiCapture prostate cancer test was evaluated in approximately 750 patient samples, demonstrating a clinical accuracy of 85%, indicating strong clinical utility in oncology diagnostics that can aid physicians in making more precise clinical decisions.
- Significant Market Potential: With U.S. national expenditures for prostate cancer care exceeding $20 billion annually, the launch of EpiCapture positions Trinity Biotech to enter the precision oncology diagnostics market, addressing growing market demand and driving future revenue growth for the company.
- Non-Invasive Testing Advantage: EpiCapture, as a urine liquid biopsy test, offers a simpler and non-invasive method for assessing high-grade prostate cancer risk compared to high-resolution MRI scans and needle biopsies, potentially attracting more patients to opt for this testing.
- Future Commercialization Plans: Trinity plans to commercialize EpiCapture as a proprietary Laboratory Developed Test (LDT) through a New York State Department of Health-certified diagnostic reference laboratory, which will expedite the rollout of precision oncology testing services across the U.S.
See More
Trinity Biotech Enters $25 Million Equity Purchase Agreement
- Financing Agreement Details: Trinity Biotech has entered into a $25 million standby equity purchase agreement with an affiliate of Yorkville Advisors Global, allowing the company to sell newly issued American Depositary Shares over a 36-month period, aimed at supporting its commercialization and R&D initiatives.
- Pricing Mechanism: Under the agreement, shares issued will be priced at either 97% of the lowest daily volume-weighted average price during a three-day pricing period or 95% of the VWAP during a single-day pricing period, providing the company with flexible financing options to potentially lower costs.
- Market Reaction: Following the announcement of the agreement, Trinity Biotech's shares dipped slightly to $0.75 in pre-market trading, reflecting a cautious market sentiment regarding the financing arrangement while highlighting investor interest in the company's future prospects.
- Strategic Implications: This financing agreement not only provides essential funding for Trinity Biotech but also supports its commercialization efforts in areas such as HIV testing, further solidifying its market position in the biotechnology sector.
See More
Trinity Biotech PLC Secures $25 Million SEPA with Yorkville Advisors Global Affiliate
Investment Announcement: Trinity Biotech PLC has entered into a $25 million SEPA with an affiliate of Yorkville Advisors.
Financial Partnership: The agreement involves a financing partnership aimed at supporting Trinity Biotech's growth and operational needs.
See More
Trinity Biotech Faces Nasdaq Compliance Issue
- Compliance Notice: On February 19, 2026, Trinity Biotech received a notice indicating it no longer meets Nasdaq's minimum public float requirement of $15 million, which poses a risk to its continued listing on the exchange.
- Market Reaction: Despite the compliance issue, Trinity Biotech's stock price rose due to an order for 9 million TrinScreen HIV tests, reflecting market confidence in product demand and potentially alleviating investor concerns regarding compliance deficiencies.
- Rating Dynamics: Seeking Alpha's Quant Rating on Trinity Biotech reveals mixed market sentiment about its future performance; while compliance issues persist, the increase in orders may influence investor perceptions positively.
- Financial Disclosure: Financial information from Trinity Biotech indicates its market performance; despite compliance challenges, the expansion of its product line and growth in orders may provide financial support to help navigate current compliance pressures.
See More
Trinity Biotech Reports FY 2025 Financial Results
- Revenue Decline: Trinity Biotech reported FY 2025 revenue of $43.8 million, a 28.9% year-over-year decrease, indicating significant sales challenges amid intensified market competition and weak product demand, which may impact future liquidity.
- Increased Net Loss: The company recorded a net loss of $37.4 million, up from $31.8 million in 2024, which included a one-off IFRS charge of $10 million related to modifications in Perceptive financing arrangements, highlighting financial management pressures.
- Adjusted EBITDA Improvement: The adjusted EBITDA for 2025 was negative $5.9 million, an improvement from negative $11.3 million in 2024, suggesting some progress in cost control despite the overall financial situation remaining challenging.
- Financing Agreement Signed: Trinity Biotech entered into a $25 million standby equity purchase agreement with investors to strengthen its capital structure and provide operational funding, reflecting proactive measures in seeking financial stability.
See More
Trinity Biotech Appoints New Head of North America Operations
- Executive Appointment: Trinity Biotech has appointed Jerry Lydon as Head of North America Commercial Operations, aiming to enhance revenue growth and profitability in its core diagnostics business, reflecting ongoing progress in the company's Comprehensive Transformation Plan.
- Product Upgrade: The Premier HbA1c 9210™ platform has received the prestigious
See More
Trinity Biotech Announces Positive Results for Enhanced Prostate Cancer Test
- Clinical Study Results: Trinity Biotech's EpiCapture prostate cancer test was evaluated in approximately 750 patient samples, demonstrating a clinical accuracy of 85%, indicating strong clinical utility in oncology diagnostics that can aid physicians in making more precise clinical decisions.
- Significant Market Potential: With U.S. national expenditures for prostate cancer care exceeding $20 billion annually, the launch of EpiCapture positions Trinity Biotech to enter the precision oncology diagnostics market, addressing growing market demand and driving future revenue growth for the company.
- Non-Invasive Testing Advantage: EpiCapture, as a urine liquid biopsy test, offers a simpler and non-invasive method for assessing high-grade prostate cancer risk compared to high-resolution MRI scans and needle biopsies, potentially attracting more patients to opt for this testing.
- Future Commercialization Plans: Trinity plans to commercialize EpiCapture as a proprietary Laboratory Developed Test (LDT) through a New York State Department of Health-certified diagnostic reference laboratory, which will expedite the rollout of precision oncology testing services across the U.S.
See More
Trinity Biotech Enters $25 Million Equity Purchase Agreement
- Financing Agreement Details: Trinity Biotech has entered into a $25 million standby equity purchase agreement with an affiliate of Yorkville Advisors Global, allowing the company to sell newly issued American Depositary Shares over a 36-month period, aimed at supporting its commercialization and R&D initiatives.
- Pricing Mechanism: Under the agreement, shares issued will be priced at either 97% of the lowest daily volume-weighted average price during a three-day pricing period or 95% of the VWAP during a single-day pricing period, providing the company with flexible financing options to potentially lower costs.
- Market Reaction: Following the announcement of the agreement, Trinity Biotech's shares dipped slightly to $0.75 in pre-market trading, reflecting a cautious market sentiment regarding the financing arrangement while highlighting investor interest in the company's future prospects.
- Strategic Implications: This financing agreement not only provides essential funding for Trinity Biotech but also supports its commercialization efforts in areas such as HIV testing, further solidifying its market position in the biotechnology sector.
See More
Trinity Biotech PLC Secures $25 Million SEPA with Yorkville Advisors Global Affiliate
Investment Announcement: Trinity Biotech PLC has entered into a $25 million SEPA with an affiliate of Yorkville Advisors.
Financial Partnership: The agreement involves a financing partnership aimed at supporting Trinity Biotech's growth and operational needs.
See More
Trinity Biotech Faces Nasdaq Compliance Issue
- Compliance Notice: On February 19, 2026, Trinity Biotech received a notice indicating it no longer meets Nasdaq's minimum public float requirement of $15 million, which poses a risk to its continued listing on the exchange.
- Market Reaction: Despite the compliance issue, Trinity Biotech's stock price rose due to an order for 9 million TrinScreen HIV tests, reflecting market confidence in product demand and potentially alleviating investor concerns regarding compliance deficiencies.
- Rating Dynamics: Seeking Alpha's Quant Rating on Trinity Biotech reveals mixed market sentiment about its future performance; while compliance issues persist, the increase in orders may influence investor perceptions positively.
- Financial Disclosure: Financial information from Trinity Biotech indicates its market performance; despite compliance challenges, the expansion of its product line and growth in orders may provide financial support to help navigate current compliance pressures.
See More
